Company Info

Roche

Drug Discovery & Development

Overview

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

0 Contributors1 / 0

No authors found

1 / 0

21 Contributions1 / 2

COVID-19 Testing

Roche Obtains CE Mark for the SARS-CoV-2 Antigen Self Test Nasal Allowing for Rapid Self Testing of COVID-19 At Home

Roche

PR-M06-21-027Jun 22, 2021

Clinical Trials

New Data from Phase IIIb Study Reinforces Safety Profile of Roche’s Hemlibra in People with Haemophilia A

Roche

PR-M07-20-NI-020Jul 13, 2020

COVID-19 Antibody Testing

Roche's Highly Accurate Antibody Test for COVID-19 Goes Live at More than 20 Initial Lab Sites in the U.S.

Roche

PR-M05-20-NI-035-1541May 22, 2020

FDA Approval

Roche Receives FDA Approval for Cobas HPV Test to Identify Women at Risk for Cervical Cancer

Roche

PR-M04-20-NI-031Apr 22, 2020

COVID-19

Roche Initiates Phase III Clinical Trial of Actemra/RoActemra in Patients with Severe COVID-19 Pneumonia

Roche

PR-M03-20-NI-030-1678Mar 19, 2020

Roche Ships 400,000 Coronavirus Test Kits to U.S.

Roche

PR-M03-20-NI-027Mar 17, 2020

Clinical Trials

Roche’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial

Roche

PR-M01-20-NI-036Jan 23, 2020

Oncology

Roche Receives CHMP Positive Opinion for New Tecentriq-based Combination Therapy as an Initial Treatment for Most Common Form of Advanced Lung Cancer

Roche

PR-M08-19-NI-004Aug 01, 2019

Leadership

Changes in Roche's Board of Directors and Corporate Executive Committee

Roche

PR-M06-19-NI-008Jun 12, 2019

Companion Diagnostics

Roche to Develop Companion Diagnostic Test to Help Identify Patients Eligible for Anti-PD-1 Therapy Based on Biomarker Expression, Not Location, of Solid Tumors

Roche

PR-M12-18-NI-050Dec 14, 2018

FDA Approval

FDA Approves Roche's Tecentriq in Combination with Avastin and Chemotherapy for the Initial Treatment of People with a Specific Type of Metastatic Lung Cancer

Roche

PR-M12-18-NI-041Dec 12, 2018

FDA Approval

Roche's cobas HPV Test receives FDA approval for first-line cervical cancer screening using SurePath preservative fluid

Roche

PR-M08-18-NI-006Aug 06, 2018

Antibiotic Resistance

Roche PCT assay cleared for expanded use - Important tool in antibiotic resistance crisis

Roche

PR-M07-18-NI-049Jul 16, 2018

Oncology

Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening for metastatic triple negative breast cancer

Roche

PR-M07-18-NI-021Jul 09, 2018

M&A

Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology

Roche

PR-M06-18-NI-073Jun 22, 2018

Zika Test

FDA approves additional claim for Roche cobas Zika test

Roche

PR-M05-18-NI-061May 16, 2018

Drug Development

Roche expands indication for cobas® EGFR Mutation Test v2 as a companion diagnostic with TAGRISSO®

Roche

PR-M04-18-NI-84Apr 24, 2018

FDA

Roche receives FDA clearance for cobas® CT/NG for cobas® 6800/8800 Systems

Roche

PR-M04-18-NI-60Apr 18, 2018

Diagnostics Information

Roche achieves two major milestones in the evolution of decision support platform

Roche

PR-M03-18-NI-022-4621Mar 06, 2018

FDA

Roche receives FDA clearance for Factor II and Factor V test on the cobas® 4800 system

Roche

PR-M02-18-NI-66Feb 19, 2018

1 / 2